Ziopharm Oncology Inc. (NASDAQ:ZIOP) shares traded down 3% during trading on Thursday . The company traded as low as $4.92 and last traded at $4.92, with a volume of 964,637 shares changing hands. The stock had previously closed at $5.07.

A number of research analysts have commented on the company. Mizuho reaffirmed a “neutral” rating and set a $5.00 price target (down previously from $7.00) on shares of Ziopharm Oncology in a research report on Monday, July 18th. Griffin Securities reaffirmed a “buy” rating and set a $21.00 price target on shares of Ziopharm Oncology in a research report on Tuesday, June 7th. Wells Fargo & Co. raised Ziopharm Oncology from an “underperform” rating to a “market perform” rating in a research report on Wednesday, August 10th. Raymond James Financial Inc. assumed coverage on Ziopharm Oncology in a report on Thursday, June 2nd. They set a “market perform” rating on the stock. Finally, Zacks Investment Research upgraded Ziopharm Oncology from a “sell” rating to a “hold” rating in a report on Wednesday, May 11th. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $9.75.

The firm has a 50 day moving average of $5.15 and a 200-day moving average of $6.74. The company’s market cap is $644.65 million.

Ziopharm Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Tuesday, August 9th. The biotechnology company reported ($1.01) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by $0.90. During the same period in the prior year, the company posted ($0.11) EPS. The company earned $1.70 million during the quarter, compared to the consensus estimate of $1.52 million. The company’s quarterly revenue was up 525.0% compared to the same quarter last year. Analysts forecast that Ziopharm Oncology Inc. will post ($1.15) earnings per share for the current fiscal year.

A hedge fund recently raised its stake in Ziopharm Oncology stock. Morgan Stanley increased its stake in Ziopharm Oncology Inc. (NASDAQ:ZIOP) by 5.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,618,205 shares of the biotechnology company’s stock after buying an additional 78,583 shares during the period. Morgan Stanley owned 1.25% of Ziopharm Oncology worth $13,447,000 at the end of the most recent reporting period.

ZIOPHARM Oncology, Inc is a biopharmaceutical company. The Company is seeking to acquire, develop and commercialize, on its own or with partners, a portfolio of cancer therapies through synthetic immuno-oncology. Its clinical-stage product candidate, Ad-RTS-IL-12, is used with the oral activator veledimex.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.